ReviewBlood advances2022
Bite-size introduction to canine hematologic malignancies.
Review in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma.Molecular cancer therapeutics · 2026Article
- The microenvironment in canine mast cell tumors: association between tumor-associated tissue eosinophilia and histological grade.Frontiers in veterinary science · 2026Article
- Immune profiling of canine B cell lymphoma reveals cross-species conservation of prognostic markers.Scientific reports · 2025Article
- What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine-The Current State of Knowledge.Cancers · 2025Review
- Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma.Cancer immunology, immunotherapy : CII · 2025Article
- Intertumoral heterogeneity of the immune microenvironment in high grade canine mast cell tumors.Veterinary oncology (London, England) · 2025Article
- Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- An Evaluation of Hemostatic Dysregulation in Canine Multicentric Lymphoma.Animals : an open access journal from MDPI · 2024Article
- Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog.Molecular therapy. Methods & clinical development · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Hematologic malignancies are frequently diagnosed in dogs and result in a spectrum of clinical signs associated with specific disease types. The most frequently encountered hematologic tumors in dogs include lymphoma, lymphoid and myeloid leukemias, and mast cell, plasma cell, and histiocytic neoplasias. Coupled with the heterogeneous presentations of the different categories and subtypes of canine hematologic malignancies, outcomes for these tumors are also variable. Considering this, appropriate treatment options range from active surveillance to curative intent approaches harnessing surgical, chemotherapeutic, and radiation-based modalities. The underlying pathology of many of these diseases bears remarkable resemblance to that of the corresponding diagnosis made in human patients. We introduce some of the pathogenic drivers of canine hematologic cancers alongside their clinical presentations. An overview of standard-of-care therapies for each of these diseases is also provided. As comparative oncology gains recognition as a valuable setting in which to investigate the pathogenesis of neoplasia and provide powerful, clinically relevant, immunocompetent models for the evaluation of novel therapies, the number of clinicians and scientists participating in cancer research involving dogs is expected to increase. This review aims at providing an introductory overview of canine hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.